Boyiadzis, Michael; Zhang, Mei-Jie; Chen, Karen; Abdel-Azim, Hisham; Abid, Muhammad Bilal; Aljurf, Mahmoud; Bacher, Ulrike; Badar, Talha; Badawy, Sherif M; Battiwalla, Minoo; Bejanyan, Nelli; Bhatt, Vijaya Raj; Brown, Valerie I; Castillo, Paul; Cerny, Jan; Copelan, Edward A; Craddock, Charles; Dholaria, Bhagirathbhai; Perez, Miguel Angel Diaz; Ebens, Christen L; ... (2023). Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia, 37(5), pp. 1006-1017. Springer Nature 10.1038/s41375-022-01738-3
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
s41375-022-01738-3.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy |
We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received allo-HCT using myeloablative (MAC) or reduced-intensity (RIC) conditioning in first complete remission (CR) or with primary induction failure (PIF). Patients who received MAC allo-HCT in CR after 1 induction cycle had 1.3-fold better overall survival (OS) than 2 cycles to CR and 1.47-fold better than ≥3 cycles. OS after CR in 2 or ≥3 cycles was similar. Relapse risk was 1.65-fold greater in patients receiving ≥3 cycles to achieve CR. After RIC allo-HCT, the number of induction cycles to CR did not affect OS. Compared to CR in 1 cycle, relapse risk was 1.24-1.41-fold greater in patients receiving 2 or ≥3 cycles. For patients receiving only 1 cycle to CR, consolidation therapy prior to MAC allo-HCT was associated with improved OS vs. no consolidation therapy. Detectable MRD at the time of MAC allo-HCT did not impact outcomes while detectable MRD preceding RIC allo-HCT was associated with an increased risk of relapse. For allo-HCT in PIF, OS was significantly worse than allo-HCT in CR after 1-3 cycles.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Bacher, Vera Ulrike |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1476-5551 |
Publisher: |
Springer Nature |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
01 Nov 2022 12:48 |
Last Modified: |
11 May 2023 00:12 |
Publisher DOI: |
10.1038/s41375-022-01738-3 |
Related URLs: |
|
PubMed ID: |
36310182 |
BORIS DOI: |
10.48350/174383 |
URI: |
https://boris.unibe.ch/id/eprint/174383 |
Actions (login required)
 |
Edit item |